TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46^th Annual Growth Conference.

TELA’s management is scheduled to present at the Canaccord Genuity 46^th Annual Growth Conference at 8:30 am ET on August 12^th, 2026. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Investor Contact
Louisa Smith
[email protected]

You May Also Be Interested In

• TR-069 to TR-369: Why Broadband Providers Are Making the Move
• StimCardio's NeuroPulse Study Reports Substantial Reduction in Recurrent Atrial Fibrillation Events Via Non-Invasive Wearable Neuromodulation Following Ablation
• Advise RE Reviews Budgets and Tax Treatment During Active Builds